Literature DB >> 9721206

Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions.

M Mai1, H Huang, C Reed, C Qian, J S Smith, B Alderete, R Jenkins, D I Smith, W Liu.   

Abstract

p73, a protein having substantial structural and functional similarity to p53, has recently been identified and demonstrated to be a potential tumor suppressor. Its location on human chromosome 1p36.33 implicates p73 as a candidate for neuroblastoma. Like neuroblastoma, oligodendrogliomas also show a high frequency of deletions in chromosome 1p36.3. To determine whether p73 is a potential tumor suppressor gene involved in the development of oligodendrogliomas, we performed mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. We first determined the genomic organization and the intron-exon boundary sequences of the p73 gene by long PCR, vectorette PCR, and Southern hybridization. This gene spans about 65 kb with a large first intron. Primer pairs for the amplification of each of the 13 p73 encoding exons were designed in corresponding introns. The amplicons were then analyzed using the denaturing high-performance liquid chromatography system for mutations in the p73 gene. Twenty oligodendroglioma samples with 1p36.3 deletions were screened, but no mutations were detected except for several polymorphisms. It is thus clear that p73 is not a candidate gene for oligodendroglioma despite its location in the frequently deleted 1p36.3 region. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721206     DOI: 10.1006/geno.1998.5387

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  15 in total

1.  Mutation and expression of the p51 gene in human lung cancer.

Authors:  M Tani; K Shimizu; C Kawahara; T Kohno; O Ishimoto; S Ikawa; J Yokota
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation.

Authors:  G Fontemaggi; A Gurtner; S Strano; Y Higashi; A Sacchi; G Piaggio; G Blandino
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 3.  p53: twenty five years understanding the mechanism of genome protection.

Authors:  M Gomez-Lazaro; F J Fernandez-Gomez; J Jordán
Journal:  J Physiol Biochem       Date:  2004-12       Impact factor: 4.158

Review 4.  Molecular pathogenesis of oligodendroglial tumors.

Authors:  Judith W M Jeuken; Andreas von Deimling; Pieter Wesseling
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

Review 5.  Molecular pathogenesis of acromegaly.

Authors:  M R Drange; S Melmed
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 6.  Genetics of brain neoplasms.

Authors:  J R Shapiro
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

8.  A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism.

Authors:  Zach Serber; Helen C Lai; Annie Yang; Horng D Ou; Martina S Sigal; Alexander E Kelly; Beatrice D Darimont; Pascal H G Duijf; Hans Van Bokhoven; Frank McKeon; Volker Dötsch
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

9.  Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data.

Authors:  Filip Kramar; Zuzana Zemanova; Kyra Michalova; Libuse Babicka; Sarka Ransdorfova; Petr Hrabal; Petr Kozler
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

10.  Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours.

Authors:  Z Dong; Jc-S Pang; M H Ng; W S Poon; L Zhou; H-K Ng
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.